RNF32
gene geneOn this page
Also known as FKSG33HSD15LMBR2
Summary
RNF32 (ring finger protein 32, HGNC:17118) is a protein-coding gene on chromosome 7q36.3, encoding RING finger protein 32 (Q9H0A6). May play a role in sperm formation.
The protein encoded by this gene contains two RING ring finger motifs. RING finger motifs are present in a variety of functionally distinct proteins and are known to be involved in protein-DNA or protein-protein interactions. This gene was found to be expressed during spermatogenesis, most likely in spermatocytes and/or in spermatids. Alternative splicing of this gene results in multiple transcript variants.
Source: NCBI Gene 140545 — RefSeq curated summary.
At a glance
- GWAS associations: 1
- Clinical variants (ClinVar): 22 total
- Dosage sensitivity (ClinGen): haploinsufficiency dosage sensitivity unlikely, triplosensitivity no evidence
- MANE Select transcript:
NM_030936
Identifiers
Gene identifiers
| Field | Value |
|---|---|
| HGNC ID | HGNC:17118 |
| Approved symbol | RNF32 |
| Name | ring finger protein 32 |
| Location | 7q36.3 |
| Locus type | gene with protein product |
| Status | Approved |
| Aliases | FKSG33, HSD15, LMBR2 |
| Ensembl gene | ENSG00000105982 |
| Ensembl biotype | protein_coding |
| OMIM | 610241 |
| Entrez | 140545 |
Gene structure
Transcript identifiers
Ensembl transcripts: 24 — 18 protein_coding, 4 protein_coding_CDS_not_defined, 1 nonsense_mediated_decay, 1 retained_intron
ENST00000311822, ENST00000317955, ENST00000392741, ENST00000392743, ENST00000392747, ENST00000404282, ENST00000405335, ENST00000432459, ENST00000439609, ENST00000463028, ENST00000469382, ENST00000472537, ENST00000480011, ENST00000493999, ENST00000886327, ENST00000886328, ENST00000886329, ENST00000886330, ENST00000886331, ENST00000886332, ENST00000886333, ENST00000886334, ENST00000972044, ENST00000972045
RefSeq mRNA: 5 — MANE Select: NM_030936
NM_001184996, NM_001184997, NM_001308273, NM_001308274, NM_030936
CCDS: CCDS5944, CCDS78292, CCDS78293
Canonical transcript exons
ENST00000317955 — 9 exons
| Exon | Start | End |
|---|---|---|
| ENSE00001346774 | 156640774 | 156640811 |
| ENSE00003461428 | 156658462 | 156658570 |
| ENSE00003477849 | 156658128 | 156658252 |
| ENSE00003485634 | 156643801 | 156643892 |
| ENSE00003493996 | 156644499 | 156644757 |
| ENSE00003524487 | 156654576 | 156654718 |
| ENSE00003535407 | 156657541 | 156657573 |
| ENSE00003555739 | 156676419 | 156677130 |
| ENSE00003634462 | 156675696 | 156675863 |
Expression profiles
Bgee: expression breadth ubiquitous, 184 present calls, max score 95.84.
FANTOM5 (CAGE): breadth broad, TPM avg 1.6648 / max 136.2277, expressed in 788 samples.
FANTOM5 promoters (5 alternative TSS)
| Promoter ID | TPM avg | Samples expressed |
|---|---|---|
| 82267 | 0.7696 | 407 |
| 82266 | 0.4993 | 218 |
| 82265 | 0.2330 | 97 |
| 82268 | 0.1581 | 62 |
| 82269 | 0.0048 | 3 |
Top tissues by expression
279 total, by Bgee expression score (0-100, higher = more expressed):
| Tissue | Anatomy ID | Expression score | Quality |
|---|---|---|---|
| left testis | UBERON:0004533 | 95.84 | gold quality |
| right testis | UBERON:0004534 | 95.31 | gold quality |
| sperm | CL:0000019 | 94.37 | gold quality |
| testis | UBERON:0000473 | 92.89 | gold quality |
| male germ cell | CL:0000015 | 92.13 | gold quality |
| male germ line stem cell (sensu Vertebrata) in testis | CL:0000089 ∩ UBERON:0000473 | 89.72 | gold quality |
| adult organism | UBERON:0007023 | 78.48 | gold quality |
| bronchial epithelial cell | CL:0002328 | 78.27 | gold quality |
| C1 segment of cervical spinal cord | UBERON:0006469 | 75.21 | gold quality |
| right uterine tube | UBERON:0001302 | 74.85 | gold quality |
| epithelium of bronchus | UBERON:0002031 | 73.26 | gold quality |
| primordial germ cell in gonad | CL:0000670 ∩ UBERON:0000991 | 73.11 | gold quality |
| spinal cord | UBERON:0002240 | 72.37 | gold quality |
| bronchus | UBERON:0002185 | 72.09 | gold quality |
| islet of Langerhans | UBERON:0000006 | 72.03 | gold quality |
| cortical plate | UBERON:0005343 | 72.02 | gold quality |
| left adrenal gland cortex | UBERON:0035825 | 71.15 | gold quality |
| body of stomach | UBERON:0001161 | 70.95 | gold quality |
| right lung | UBERON:0002167 | 70.66 | gold quality |
| left adrenal gland | UBERON:0001234 | 70.38 | gold quality |
| body of pancreas | UBERON:0001150 | 70.35 | gold quality |
| right adrenal gland | UBERON:0001233 | 69.92 | gold quality |
| adrenal tissue | UBERON:0018303 | 69.82 | gold quality |
| olfactory segment of nasal mucosa | UBERON:0005386 | 69.72 | gold quality |
| prefrontal cortex | UBERON:0000451 | 69.71 | gold quality |
| metanephros cortex | UBERON:0010533 | 69.66 | gold quality |
| pancreas | UBERON:0001264 | 69.57 | gold quality |
| right adrenal gland cortex | UBERON:0035827 | 69.51 | gold quality |
| anterior cingulate cortex | UBERON:0009835 | 69.45 | gold quality |
| amygdala | UBERON:0001876 | 69.42 | gold quality |
Single-cell (SCXA)
Detected in 3 experiment(s), a significant marker in 0.
| Experiment | Marker? | Max mean expression |
|---|---|---|
| E-MTAB-6386 | no | 75.38 |
| E-ENAD-17 | no | 41.87 |
| E-ANND-3 | no | 3.34 |
Regulation
Is transcription factor: no
miRNA regulators (miRDB)
27 targeting RNF32, top 30 by miRDB confidence (max_score; target_count = how many genes the miRNA targets in total — lower means more specific):
| miRNA | Max score | Avg score | miRNA target_count |
|---|---|---|---|
| HSA-MIR-9983-3P | 99.94 | 71.48 | 3631 |
| HSA-MIR-129-5P | 99.88 | 70.26 | 3273 |
| HSA-MIR-3941 | 99.86 | 70.54 | 2735 |
| HSA-MIR-556-3P | 99.74 | 68.75 | 1203 |
| HSA-MIR-466 | 99.67 | 70.85 | 2863 |
| HSA-MIR-1303 | 99.65 | 69.77 | 1662 |
| HSA-MIR-3685 | 99.62 | 68.83 | 1621 |
| HSA-MIR-3616-5P | 99.55 | 67.02 | 989 |
| HSA-MIR-573 | 99.55 | 67.44 | 955 |
| HSA-MIR-3120-3P | 99.54 | 70.28 | 2669 |
| HSA-MIR-4672 | 99.50 | 71.58 | 2893 |
| HSA-MIR-21-5P | 99.46 | 70.54 | 1035 |
| HSA-MIR-1912-3P | 99.32 | 67.40 | 936 |
| HSA-MIR-4477B | 99.23 | 70.49 | 1733 |
| HSA-MIR-10399-5P | 99.17 | 69.87 | 2610 |
| HSA-MIR-6504-3P | 99.17 | 69.31 | 2891 |
| HSA-MIR-4292 | 99.16 | 65.57 | 1767 |
| HSA-MIR-6791-5P | 99.16 | 65.92 | 1844 |
| HSA-MIR-670-3P | 99.03 | 68.88 | 2404 |
| HSA-MIR-155-3P | 99.03 | 67.99 | 924 |
| HSA-MIR-1295B-5P | 99.03 | 67.50 | 810 |
| HSA-MIR-181A-2-3P | 98.91 | 67.60 | 1168 |
| HSA-MIR-1279 | 97.83 | 67.50 | 1898 |
| HSA-MIR-4786-5P | 97.45 | 67.89 | 924 |
| HSA-MIR-122-5P | 97.23 | 64.92 | 1024 |
| HSA-MIR-4433B-3P | 97.22 | 63.62 | 663 |
| HSA-MIR-6802-5P | 94.94 | 65.95 | 366 |
Functional genomics
ClinGen dosage: haploinsufficiency 40 (dosage sensitivity unlikely), triplosensitivity 0 (no evidence). ClinGen Gene Dosage Map
Literature-anchored findings (GeneRIF, showing 1)
- molecular cloning of a RING domain protein expressed during sperm formation (PMID:11890671)
Cross-species orthologs
3 orthologs
| Organism | Symbol | Gene ID |
|---|---|---|
| danio_rerio | rnf32 | ENSDARG00000060035 |
| mus_musculus | Rnf32 | ENSMUSG00000029130 |
| rattus_norvegicus | Rnf32 | ENSRNOG00000005691 |
Protein
Protein identifiers
RING finger protein 32 — Q9H0A6 (reviewed: Q9H0A6)
All UniProt accessions (4): Q9H0A6, C9JXI4, E9PES2, G5E940
UniProt curated annotations — full annotation on UniProt →
Function. May play a role in sperm formation.
Subcellular location. Cytoplasm.
Tissue specificity. Highly expressed in testis, less abundant in ovary.
Miscellaneous. May be produced at very low levels due to a premature stop codon in the mRNA, leading to nonsense-mediated mRNA decay.
Isoforms (5)
| UniProt ID | Names | Canonical? |
|---|---|---|
| Q9H0A6-1 | 1 | yes |
| Q9H0A6-2 | 2 | |
| Q9H0A6-4 | 3 | |
| Q9H0A6-5 | 4 | |
| Q9H0A6-6 | 5 |
RefSeq proteins (5): NP_001171925, NP_001171926, NP_001295202, NP_001295203, NP_112198* (*=MANE)
Domains & families (InterPro)
| ID | Name | Type |
|---|---|---|
| IPR000048 | IQ_motif_EF-hand-BS | Binding_site |
| IPR001841 | Znf_RING | Domain |
| IPR013083 | Znf_RING/FYVE/PHD | Homologous_superfamily |
| IPR027370 | Znf-RING_euk | Domain |
| IPR042862 | RNF32 | Family |
Pfam: PF00612, PF13445, PF13639
UniProt features (14 total): splice variant 6, sequence variant 3, zinc finger region 2, chain 1, domain 1, sequence conflict 1
Structure
Experimental structures (PDB)
0 structures.
Predicted structure (AlphaFold)
| Model | pLDDT | Fraction very-high |
|---|---|---|
| AF-Q9H0A6-F1 | 79.81 | 0.47 |
Function
Pathways and Gene Ontology
Reactome pathways
0 pathways
MSigDB gene sets: 91 (showing top):
TGCGCANK_UNKNOWN, GRAESSMANN_APOPTOSIS_BY_SERUM_DEPRIVATION_UP, SCHAEFFER_PROSTATE_DEVELOPMENT_48HR_UP, SLEBOS_HEAD_AND_NECK_CANCER_WITH_HPV_UP, FONTAINE_PAPILLARY_THYROID_CARCINOMA_DN, GOCC_AGGRESOME, NUYTTEN_EZH2_TARGETS_DN, GOCC_INCLUSION_BODY, GAVIN_FOXP3_TARGETS_CLUSTER_P7, ZHAN_MULTIPLE_MYELOMA_MS_UP, PEDERSEN_METASTASIS_BY_ERBB2_ISOFORM_6, ZWANG_TRANSIENTLY_UP_BY_2ND_EGF_PULSE_ONLY, CREB3L4_TARGET_GENES, FOXD2_TARGET_GENES, GLI3_TARGET_GENES
GO Biological Process (0):
GO Molecular Function (3): zinc ion binding (GO:0008270), protein binding (GO:0005515), metal ion binding (GO:0046872)
GO Cellular Component (5): endosome (GO:0005768), cytosol (GO:0005829), aggresome (GO:0016235), nuclear body (GO:0016604), cytoplasm (GO:0005737)
GO top-level categories
Rollup of top GO terms by namespace:
| Category | Terms |
|---|---|
| cellular anatomical structure | 2 |
| transition metal ion binding | 1 |
| binding | 1 |
| cation binding | 1 |
| endomembrane system | 1 |
| cytoplasmic vesicle | 1 |
| cytoplasm | 1 |
| inclusion body | 1 |
| nucleoplasm | 1 |
| intracellular membraneless organelle | 1 |
| intracellular anatomical structure | 1 |
Protein interactions and networks
STRING
490 interactions, top by confidence (×1000):
| Protein A | Protein B | Partner UniProt | Score |
|---|---|---|---|
| RNF32 | LMBR1 | Q8WVP7 | 796 |
| RNF32 | NOM1 | Q5C9Z4 | 775 |
| RNF32 | RBM33 | Q96EV2 | 655 |
| RNF32 | UBE3C | Q15386 | 551 |
| RNF32 | LZTS3 | O60299 | 520 |
| RNF32 | MNX1 | P50219 | 518 |
| RNF32 | ACSM1 | Q08AH1 | 517 |
| RNF32 | DLD | P09622 | 492 |
| RNF32 | ABT1 | Q9ULW3 | 469 |
| RNF32 | SHH | Q15465 | 453 |
| RNF32 | BLTP2 | Q14667 | 406 |
| RNF32 | LRRC72 | A6NJI9 | 405 |
| RNF32 | DNAJB6 | O75190 | 384 |
| RNF32 | CSTL1 | Q9H114 | 373 |
| RNF32 | ZP2 | Q05996 | 373 |
IntAct
38 interactions, top by confidence:
| A | B | Type | Score |
|---|---|---|---|
| RNF32 | FBXL12 | psi-mi:“MI:0407”(direct interaction) | 0.530 |
| PRAM1 | RNF32 | psi-mi:“MI:0407”(direct interaction) | 0.530 |
| RNF32 | STAMBPL1 | psi-mi:“MI:0407”(direct interaction) | 0.530 |
| RNF32 | FBXL12 | psi-mi:“MI:0915”(physical association) | 0.530 |
| PRAM1 | RNF32 | psi-mi:“MI:0915”(physical association) | 0.530 |
| RNF32 | STAMBPL1 | psi-mi:“MI:0915”(physical association) | 0.530 |
| RNF32 | HNRNPDL | psi-mi:“MI:0915”(physical association) | 0.400 |
| RNF32 | H1-4 | psi-mi:“MI:0915”(physical association) | 0.400 |
| RNF32 | IGLC2 | psi-mi:“MI:0915”(physical association) | 0.400 |
| RNF32 | HIP2 | psi-mi:“MI:0915”(physical association) | 0.370 |
| RNF32 | A2M | psi-mi:“MI:0915”(physical association) | 0.370 |
| RNF32 | CDC37 | psi-mi:“MI:0915”(physical association) | 0.370 |
| NOS3 | RNF32 | psi-mi:“MI:0915”(physical association) | 0.370 |
| RNF32 | PSEN2 | psi-mi:“MI:0915”(physical association) | 0.370 |
| APP | RNF32 | psi-mi:“MI:0915”(physical association) | 0.370 |
| APOE | RNF32 | psi-mi:“MI:0915”(physical association) | 0.370 |
| BLMH | RNF32 | psi-mi:“MI:0915”(physical association) | 0.370 |
| CDK5 | RNF32 | psi-mi:“MI:0915”(physical association) | 0.370 |
| ECSIT | RNF32 | psi-mi:“MI:0915”(physical association) | 0.370 |
| ELAVL3 | RNF32 | psi-mi:“MI:0915”(physical association) | 0.370 |
| EXOSC1 | RNF32 | psi-mi:“MI:0915”(physical association) | 0.370 |
| RNF32 | GCDH | psi-mi:“MI:0915”(physical association) | 0.370 |
| RNF32 | IFIT5 | psi-mi:“MI:0915”(physical association) | 0.370 |
| LONP1 | RNF32 | psi-mi:“MI:0915”(physical association) | 0.370 |
| RNF32 | OGA | psi-mi:“MI:0915”(physical association) | 0.370 |
| RNF32 | PRDX2 | psi-mi:“MI:0915”(physical association) | 0.370 |
| RNF32 | RAD23A | psi-mi:“MI:0915”(physical association) | 0.370 |
| LZTS2 | RNF32 | psi-mi:“MI:0915”(physical association) | 0.370 |
| FBXW4 | RNF32 | psi-mi:“MI:0915”(physical association) | 0.370 |
| RNF32 | CYP2C9 | psi-mi:“MI:0915”(physical association) | 0.370 |
BioGRID (52): RNF32 (Reconstituted Complex), RNF32 (Proximity Label-MS), RNF32 (Proximity Label-MS), RNF32 (Affinity Capture-MS), IGLC2 (Affinity Capture-MS), RNF32 (Reconstituted Complex), RNF32 (Two-hybrid), APP (Reconstituted Complex), RNF32 (Two-hybrid), RNF32 (Two-hybrid), RNF32 (Two-hybrid), RNF32 (Two-hybrid), APP (Two-hybrid), APOE (Two-hybrid), BLMH (Two-hybrid)
ESM2 similar proteins: A6QQJ8, A9JTG5, B0F0H3, D3YY23, E0X9N4, E6ZIJ1, E9QAM5, O14976, P39428, P97874, Q13064, Q13077, Q17RB8, Q1L5Z9, Q1L8G6, Q1LXR6, Q2TA39, Q4R5T4, Q5FWT8, Q5NU13, Q5R7G8, Q5REG4, Q5T124, Q5ZA07, Q60764, Q6AXL8, Q6GLD9, Q6IDS6, Q6NZR5, Q76LS9, Q80V91, Q8IZP6, Q8K1S6, Q8N5J2, Q8N9I9, Q8R512, Q8WWL2, Q99KY4, Q9CQR5, Q9D572
Diamond homologs: Q4R5T4, Q94AK4, Q9H0A6, Q9JIT1, Q9FGI1
SIGNOR signaling
1 interactions.
| A | Effect | B | Mechanism |
|---|---|---|---|
| Ub:E2 | “up-regulates activity” | RNF32 | ubiquitination |
Disease & clinical
Clinical variants and AI predictions
ClinVar
22 variants total. Per-class counts are floors (≥ shown; pagination cap):
| Classification | Count (floor) |
|---|---|
| Pathogenic | 0 |
| Likely pathogenic | 0 |
| Uncertain significance | 18 |
| Likely benign | 1 |
| Benign | 0 |
Top pathogenic / likely-pathogenic (0)
SpliceAI
2087 predictions. Top by Δscore:
| Variant | Effect | Δscore |
|---|---|---|
| 7:156644758:GT:G | donor_loss | 1.0000 |
| 7:156644759:T:TC | donor_loss | 1.0000 |
| 7:156657652:GCTCC:G | donor_gain | 1.0000 |
| 7:156675861:CAGG:C | donor_loss | 1.0000 |
| 7:156675864:GT:G | donor_loss | 1.0000 |
| 7:156675865:T:A | donor_loss | 1.0000 |
| 7:156640830:G:T | donor_gain | 0.9900 |
| 7:156640835:G:T | donor_gain | 0.9900 |
| 7:156640840:A:T | donor_gain | 0.9900 |
| 7:156644497:AG:A | acceptor_gain | 0.9900 |
| 7:156644498:GG:G | acceptor_gain | 0.9900 |
| 7:156644756:GG:G | donor_gain | 0.9900 |
| 7:156644757:GG:G | donor_gain | 0.9900 |
| 7:156644758:G:GG | donor_gain | 0.9900 |
| 7:156654734:GG:G | donor_gain | 0.9900 |
| 7:156654735:GG:G | donor_gain | 0.9900 |
| 7:156655148:G:GG | donor_gain | 0.9900 |
| 7:156675694:A:AG | acceptor_gain | 0.9900 |
| 7:156675695:G:GG | acceptor_gain | 0.9900 |
| 7:156640818:A:T | donor_gain | 0.9800 |
| 7:156640943:GCT:G | donor_gain | 0.9800 |
| 7:156654695:G:GT | donor_gain | 0.9800 |
| 7:156655059:T:G | donor_gain | 0.9800 |
| 7:156658544:T:G | donor_gain | 0.9800 |
| 7:156675692:TCA:T | acceptor_loss | 0.9800 |
| 7:156675695:G:GA | acceptor_loss | 0.9800 |
| 7:156640830:G:GT | donor_gain | 0.9700 |
| 7:156644493:TTTTA:T | acceptor_loss | 0.9700 |
| 7:156644494:TTTAG:T | acceptor_loss | 0.9700 |
| 7:156644495:TTA:T | acceptor_loss | 0.9700 |
AlphaMissense
0 scored. Top likely-pathogenic:
dbSNP variants (sampled 300 via entrez): RS1000084089 (7:156655188 T>C), RS1000198825 (7:156667919 C>T), RS1000282111 (7:156667347 T>C), RS1000291425 (7:156667613 A>G), RS1000311672 (7:156639803 G>A), RS1000326058 (7:156661763 G>A), RS1000351832 (7:156655428 T>C), RS1000461957 (7:156661468 C>T), RS1000476901 (7:156672461 A>G), RS1000532362 (7:156676826 A>G), RS1000575566 (7:156672249 G>A), RS1000620344 (7:156665967 A>G), RS1000804997 (7:156660352 C>G,T), RS1000846412 (7:156638850 T>C), RS1000888263 (7:156676905 G>A,C)
Disease associations
OMIM: gene MIM:610241 | disease phenotypes:
GenCC curated gene-disease
Mondo (0):
Orphanet (0):
HPO phenotypes
0 total (0 of 0 shown, HPO-id order):
GWAS associations
1 associations (top):
| Study | Trait | p-value |
|---|---|---|
| GCST003372_34 | Glomerular filtration rate (creatinine) | 1.000000e-09 |
Drugs & pharmacology
Drug and pharmacology data
Is drug target: no
PharmGKB: 1 entry (VIP=true, CPIC=false)
CTD chemical–gene interactions
26 total (human), top 26 by PubMed support.
| Chemical | Actions (top 5) | PubMed papers |
|---|---|---|
| methylmercuric chloride | decreases expression | 1 |
| bisphenol A | decreases expression | 1 |
| trichostatin A | decreases expression | 1 |
| tris(2-butoxyethyl) phosphate | affects expression | 1 |
| sodium arsenite | affects acetylation, affects methylation | 1 |
| butyraldehyde | decreases expression | 1 |
| pentanal | decreases expression | 1 |
| di-n-butylphosphoric acid | affects expression | 1 |
| CGP 52608 | affects binding, increases reaction | 1 |
| monomethylarsonous acid | affects methylation, affects acetylation | 1 |
| 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide | affects cotreatment, increases expression | 1 |
| dorsomorphin | affects cotreatment, increases expression | 1 |
| jinfukang | increases expression | 1 |
| Leflunomide | decreases expression | 1 |
| Air Pollutants | increases abundance, increases expression | 1 |
| Benzo(a)pyrene | decreases expression | 1 |
| Estradiol | affects cotreatment, increases expression | 1 |
| Folic Acid | decreases expression | 1 |
| Formaldehyde | increases expression | 1 |
| Hydrogen Peroxide | decreases expression | 1 |
| Mercuric Chloride | increases expression, affects cotreatment | 1 |
| Smoke | increases abundance, increases expression | 1 |
| Tetrachlorodibenzodioxin | affects cotreatment, increases expression | 1 |
| Tobacco Smoke Pollution | decreases expression | 1 |
| Okadaic Acid | decreases expression | 1 |
| Acrylamide | increases expression | 1 |
Clinical trials (associated diseases)
0 trials via MONDO — disease-level, not drug-specific.
Related Atlas pages
No linked Atlas pages yet — the cross-entity mesh grows as the corpus expands.